BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38548131)

  • 1. Outcomes in Patients with Macrotrabecular-Massive Subtype Hepatocellular Carcinoma Treated with Yttrium-90 Transarterial Radioembolization.
    Balli HT; Piskin FC; Sozutok S; Erdoğan KE; Aikimbaev K
    J Vasc Interv Radiol; 2024 Jul; 35(7):998-1003. PubMed ID: 38548131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
    Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma.
    Yu Q; Neale M; Ungchusri E; Rothenberger NJ; Liao C; Patel M; Pillai A; Navuluri R; Ahmed O; Ha TV
    J Vasc Interv Radiol; 2024 May; 35(5):712-721.e3. PubMed ID: 38336031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
    Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
    Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
    J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.
    Gabr A; Abouchaleh N; Ali R; Baker T; Caicedo J; Katariya N; Abecassis M; Riaz A; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2018 Nov; 29(11):1502-1510.e1. PubMed ID: 30268638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization for Hepatocellular Carcinoma: A Nationwide 10-Year Experience.
    Tohme S; Bou Samra P; Kaltenmeier C; Chidi AP; Varley PR; Tsung A
    J Vasc Interv Radiol; 2018 Jul; 29(7):912-919.e2. PubMed ID: 29843996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization.
    Lee JS; Lee HA; Jeon MY; Lim TS; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Han KH; Seo YS; Kim SU
    Eur J Gastroenterol Hepatol; 2020 Jun; 32(6):739-747. PubMed ID: 31764406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm.
    Kim HC; Kim YJ; Lee JH; Suh KS; Chung JW
    J Vasc Interv Radiol; 2019 Jan; 30(1):1-8. PubMed ID: 30293734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma.
    Mulé S; Galletto Pregliasco A; Tenenhaus A; Kharrat R; Amaddeo G; Baranes L; Laurent A; Regnault H; Sommacale D; Djabbari M; Pigneur F; Tacher V; Kobeiter H; Calderaro J; Luciani A
    Radiology; 2020 Jun; 295(3):562-571. PubMed ID: 32228294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic activity assessment by
    Kim DY; Lee HW; Kang W; Kim GM; Won JY; Yun M
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1679-1684. PubMed ID: 33226706
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.